Crown Holdings reported a 6% increase in global beverage can shipments in Q3 2026, driving adjusted diluted EPS up 7% to $2.39 from $2.24 in 2025. Net sales rose to $3.7 billion, reflecting higher volumes and material cost pass-through. The company is expanding capacity in Brazil, Greece, Spain, and entering India with a new plant expected in early 2028. Crown projects full-year adjusted EPS between $8.35 and $8.45 and at least $950 million in adjusted free cash flow, supported by strong cash generation and a net leverage ratio of 2.5x EBITDA.
For readers following Crown Holdings, Inc., here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Among 134 priced Consumer Cyclical-sector US stocks, 53 rose and 80 fell today. DHI (D R Horton Inc) gained 4.67% to USD 139.88 with a typical hold time of 47 days, contrasting with GME (GameStop Corp.) which dropped 4.25% to USD 26.83 and saw 98% of Pluang order activity as sell. W (Wayfair Inc) also rose 4.21% to USD 111.80, held typically for 8 days on Pluang.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
